History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs

Drug and Alcohol Dependence

Volumn 83, Issue SUPPL. 1, 2006, Pages

  Schuster, Charles R ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Abuse liability; College on problems of drug dependence; Exempt preparations; Formulations; History; International drug treaties; Regulation

Indexed keywords

ALPRAZOLAM; AMPHETAMINE; ANXIOLYTIC AGENT; ATROPINE; ATROPINE PLUS DIPHENOXYLATE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CANNABIS; CHOLINERGIC RECEPTOR BLOCKING AGENT; COCAINE; CODEINE; DIAZEPAM; EPHEDRINE; HALAZEPAM; HYDANTOIN; HYPNOTIC AGENT; LOPERAMIDE; METHADONE; MORPHINE; NALOXONE; NARCOTIC AGENT; OPIATE; OXAZEPAM; PENTAZOCINE; PHENOTHIAZINE; PSYCHOSTIMULANT AGENT; SEDATIVE AGENT; UNINDEXED DRUG;

ANALGESIC AGENT ABUSE; ANXIETY DISORDER; ARTICLE; AVERSION; BEHAVIOR; CANNABIS ADDICTION; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COCAINE DEPENDENCE; COGNITIVE DEFECT; CONTROLLED RELEASE FORMULATION; DIARRHEA; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DEPENDENCE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG FORMULATION; DRUG INDUSTRY; DRUG LABELING; DRUG MANUFACTURE; DRUG MARKETING; DRUG SUBSTITUTION; ECONOMIC ASPECT; GOVERNMENT REGULATION; HEALTH ECONOMICS; HEROIN DEPENDENCE; HUMAN; INSOMNIA; LAW ENFORCEMENT; LICENSING; MEDICAL EDUCATION; MEDICAL SOCIETY; MORPHINE ADDICTION; MOTOR DYSFUNCTION; MULTIPLE DRUG ABUSE; OPIATE ADDICTION; PATENT; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES;

CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG THERAPY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; PRESCRIPTIONS, DRUG; SUBSTANCE-RELATED DISORDERS; WORLD HEALTH;

CANNABIS;

EID: 33646030626     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2006.01.006     Document Type: Article

References (35)

1. Abreu M.E., Bigelow G.E., Fleisher L., and Walsh S.L. Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans. Psychopharmacology (Berl.) 154 (2001) 76-84
2. Arfken C.L., Schuster C.R., and Johanson C.E. Postmarketing surveillance of abuse liability of sibutramine. Drug Alcohol Depend. 69 (2003) 169-173
3. Ator N.A., and Griffiths R.R. Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend. 70 (2003) S55-S72
4. Ayd Jr. F.J. Oxazepam: an overview. Dis. Nerv. Syst. 36 (1975) 14-16
5. Bailey H.R., Davies E., and Morrison I.J. Oxazepam in the treatment of anxiety associated with depression: results of treatment in 1600 cases (studies in depression VI). Curr. Med. Res. Opin. 7 (1981) 156-163
6. Balster R.L., and Schuster C.R. Fixed-interval schedule of cocaine reinforcement: effect of dose and infusion duration. J. Exp. Anal. Behav. 20 (1973) 119-129
7. Bliding A. Effects of different rates of absorption of two benzodiazepins on subjective and objective parameters. Significance for clinical use and risk of abuse. Eur. J. Clin. Pharmacol. 7 (1974) 201-211
8. Comer S.D., and Collins E.D. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. J. Pharmacol. Exp. Ther. 303 (2002) 695-703
9. de Wit H., Bodker B., and Ambre J. Rate of increase of plasma drug level influences subjective response in humans. Psychopharmacology (Berl.) 107 (1992) 352-358
10. de Wit H., Dudish S., and Ambre J. Subjective and behavioral effects of diazepam depend on its rate of onset. Psychopharmacology (Berl.) 112 (1993) 324-330
11. Dunsky J.L. Alfred Einhorn: the discoverer of procaine. J. Mass Dent. Soc. 46 (1997) 25-26
12. Eddy N. The National Research council Involvemennt in the Opiate Problem, 1928-1971 (1973), National Academy of Sciences, Washington, DC
13. Fabre L., and Harris R. Clinical considerations in the abuse of antianxiety and antidepressant drugs. In: Kagan F., Harwood T., Rickels K., Rudzik A., and Sorer H. (Eds). Hypnotics-Methods of Development and Evaluation (1975), Spectrum Publications, Inc., New York 283-291
14. Farre M., and Cami J. Pharmacokinetic considerations in abuse liability evaluation. Br. J. Addict. 86 (1991) 1601-1606
15. Fischman M.W., and Schuster C.R. Injection duration of cocaine in humans. Fed. Proc. (1984) 43
16. Fouks L. The clinical activity of oxazepam. Acta Psychiatr. Scand. Suppl. 274 (1978) 99-103
17. Griffiths R.R., Bigelow G.E., and Ator N.A. Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend. 70 (2003) S41-S54
18. Griffiths R.R., McLeod D.R., Bigelow G.E., Liebson I.A., and Roache J.D. Relative abuse liability of diazepam and oxazepam: behavioral and subjective dose effects. Psychopharmacology (Berl.) 84 (1984) 147-154
19. Griffiths R.R., McLeod D.R., Bigelow G.E., Liebson I.A., Roache J.D., and Nowowieski P. Comparison of diazepam and oxazepam: preference, liking and extent of abuse. J. Pharmacol. Exp. Ther. 229 (1984) 501-508
20. Griffiths R.R., Troisi J.R., Silverman K., and Mumford G.K. Multiple-choice procedure: an efficient approach for investigating drug reinforcement in humans. Behav. Pharmacol. 4 (1993) 3-13
21. Harris, L.S., in press, this issue. Exempt preparations: historical perspectives. Drug Alcohol Depend.
22. Howard-Jones N. The origins of hypodermic medication. Sci. Am. 224 (1971) 96-102
23. Hursh S.R., Galuska C.M., Winger G., and Woods J.H. The economics of drug abuse: a quantitative assessment of drug demand. Mol. Interv. 5 (2005) 20-28
24. Jaffe J. Drug addiction and drug abuse. In: Gilman A., Rall T., Nies A., and Taylor P. (Eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics (1990), Pergamon, New York 522-573
25. Jaffe J.H., Ciraulo D.A., Nies A., Dixon R.B., and Monroe L.L. Abuse potential of halazepam and of diazepam in patients recently treated for acute alcohol withdrawal. Clin. Pharmacol. Ther. 34 (1983) 623-630
26. Jaffe J.H., and O'Keeffe C. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend. 70 2 Suppl (2003) S3-S11
27. Marsch L.A., Bickel W.K., Badger G.J., Rathmell J.P., Swedberg M.D., Jonzon B., and Norsten-Hoog C. Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans. J. Pharmacol. Exp. Ther. 299 (2001) 1056-1065
28. May E.L., and Jacobson A.E. The committee on problems of drug dependence: a legacy of the National Academy of Sciences. A historical account. Drug Alcohol Depend. 23 (1989) 183-218
29. Mumford G.K., Evans S.M., Fleishaker J.C., and Griffiths R.R. Alprazolam absorption kinetics affects abuse liability. Clin. Pharmacol. Ther. 57 (1995) 356-365
30. Musto D. The American Disease: Origins of Narcotic Control (1973), Yale University Press, New Haven
31. Musto D. The history of legislative controls over opium, cocaine, and their derivatives. In: Hamowy R. (Ed). Dealing with Drugs: Consequences of Government Controls (1987), Lexington Books, Lexington, MA 37-71
32. Nutt J.G., and Jasinski D.R. Methadone-naloxone mixtures for use in methadone maintenance programs. I. An evaluation in man of their pharmacological feasibility. II. Demonstration of acute physical dependence. Clin. Pharmacol. Ther. 15 (1974) 156-166
33. Poklis A. Decline in abuse of pentazocine/tripelennamine (T's and Blues) associated with the addition of naloxone to pentazocine tablets. Drug Alcohol Depend. 14 (1984) 135-140
34. Schmitz R. Friedrich Wilhelm Serturner and the discovery of morphine. Pharm. Hist. 27 (1985) 61-74
35. Winger G., Hursh S.R., Casey K.L., and Woods J.H. Relative reinforcing strength of three N-methyl-d-aspartate antagonists with different onsets of action. J. Pharmacol. Exp. Ther. 301 (2002) 690-697